Show Table of Contents
- Catalyst: Anupam Rasayan acquires Jayhawk Fine Chemicals for $150M, entering US manufacturing and semiconductor chemicals.
- Verdict: Analysts split – Emkay calls it value accretive while consensus targets suggest 30% downside.
- Key Level: $1309.30 (all-time high resistance) vs $1240 (near-term support).
The Development
Anupam Rasayan just bought its way into America. The specialty chemical player shelled out $150 million for Jayhawk Fine Chemicals, a US-based maker of dianhydrides and polyimide intermediates used in semiconductors and high-performance materials. The enterprise value is $134 million after Jayhawk’s $16 million cash. At 9x CY24 EBITDA of $15 million, Anupam paid market rate for a strategic foothold. Management says it’s EPS accretive. The plant in Kansas becomes Anupam’s first US manufacturing footprint. The product portfolio gets an instant upgrade into less cyclical, higher-margin segments. The result? The stock jumped 4.3% on the news, kissing its all-time high of 1309.30. The rally makes sense. The company is executing its global CDMO strategy.
The Market Verdict
The smart money is split. Emkay calls the deal value accretive and shoots for 1305. Deven Choksey sees a 1230 target and says accumulate. But the consensus? Ugly. Trendlyne and MarketScreener show a 905 average target, implying 30% downside and a sell rating. The disconnect is stark: Anupam trades at 1294, above the bullish targets and miles above the bearish ones. Valuations look stretched at 97x P/E with ROE of just 5.39%. Bulls are betting the US acquisition rerates the story and justifies the premium. Bears see a stock that has doubled from its February lows and needs to take a breather. Institutional holding has already waned, down 1.06% last quarter. The table below shows the divide. Note that bullish calls predate the acquisition, while bearish targets reflect execution risk and valuation concerns. The key question: does the US asset command a higher multiple?
| Source | Rating | Target | Date/Price |
|---|---|---|---|
| Emkay | Value Accretive | 1305 | Dec 10, 2025 |
| Deven Choksey | Accumulate | 1230 | Aug 21, 2025 |
| Trendlyne Consensus | Sell | 905 | Dec 09, 2025 |
| MarketScreener | Underperform | 905 | Dec 10, 2025 |
| Current Price | – | 1294.60 | Dec 09, 2025 |
Trader’s Watchlist
Levels matter now. Resistance? $1309.30. That’s the all-time high. A break above clears the path to 1350-1400. Support holds at $1240, last week’s consolidation zone. Below that, $1200 is the line in the sand. Execution risk looms large. This is a cross-border deal that needs regulatory nods. Promoter holding is shrinking, down 2.11% last quarter. The balance sheet shows warts: 186 debtor days and ROE of just 5.39%. Bulls need Jayhawk’s margins to flow through fast. Bears wait for cracks in the core business. The financing mix includes debt and quasi-equity, so watch for leverage creeping up. High working capital remains a historical sore point. The Kansas plant integration will be key. Volume on the news day hit 560K shares, above the 200K average. That shows conviction. But can it hold?
52 Week Range
Low: ₹601.00
High: ₹1309.30
on Feb 28, 2025
on Dec 9, 2025
52 Week Low to All time High Range
Low: ₹601.00
All-time High: ₹1309.30
on Feb 28, 2025
on Dec 9, 2025
Recent Returns
1 Week
+0.80%
1 Month
+14.81%
3 Months
+14.36%
6 Months
+17.87%
YTD
+71.36%
1 Year
+64.39%
News based Sentiment:
POSITIVE
Anupam Rasayan: Record Growth & Strong Outlook in December
December was a standout month for Anupam Rasayan, characterized by exceptional financial results, a new all-time high stock price, and a significantly expanded order book. These developments collectively signal strong growth momentum and a positive trajectory for the company, making it a compelling investment story.
Anupam Rasayan India – Peer Performance Comparison
Disclaimer: This blog has been written exclusively for educational purposes and does not constitute investment advice or personal recommendations. The author is not SEBI-registered as an investment advisor. Recipients should conduct their own research and consult a qualified, SEBI-registered investment advisor before making any investment decisions. Investments in the securities market are subject to market risks; read all related documents carefully before investing.
